Story no.231OngoingHealthNotableCôte-d'Or +228 Oct → 14 Nov22 facts · 80 art.
Anti-obesity drugs in France: controls, reimbursement and off-label uses
In early November 2026, customs authorities step up parcel checks to curb trafficking of appetite suppressants such as Wegovy, while the arrival of oral anti-obesity treatments prompts economic analyses and a study on reduced consumption of sugary products among treated patients. The health risks of Ozempic and Wegovy, particularly in cases of off-label use, are highlighted, and the 100-million-euro allocation for obesity reimbursement is deemed insufficient. Influencers are then singled out for promoting these drugs to boast about their slimness, patients turn to parallel markets, and health professionals warn about weight-loss injections. In mid-November, a Lilly France campaign is suspected of covert advertising for Mounjaro, specialized obesity centers are saturated since the reimbursement of Wegovy and Mounjaro in June, and research explores new therapeutic uses while Wegovy costs more than 2,300 euros per year outside eligibility criteria.
In brief
Ongoing story bringing together 22 events nationwide, followed from 28 October 2026 to 14 November 2026. 80 articles from 23 sources (health); last updated on 14 November 2026 at 15:40.
66 articles of rated outlets · 14 unrated outside the bar · 23 sources (80 art.) · the three sides talk about it · outlets: left 5, centre 15, right 2
Angle comparison for the whole story
The three sides cover the same issue (the arrival of oral Wegovy, French enthusiasm, risks and trafficking), but differ in angle: the left prioritizes testimonies and individual health risks, the center extensively covers the Ifop poll and practical alerts, the right highlights the market explosion, side effects and economic and regulatory aspects.
Left
Highlights personal testimonies (a patient who lost weight without medication, a formerly obese person warning about Wegovy), health risks linked to off-label use and recourse to parallel markets, as well as changes in eating habits.
Centre
Extensively covers the Ifop poll (one in five French people tempted, even without being obese), health professionals' alerts on injections and harmful substances, influencers diverting medications, and customs controls against trafficking.
Right
Highlights the explosion of the appetite suppressant market and the multiplication of side effects, the non-reimbursable nature of oral Wegovy, consultation waiting times and the economic aspects of treatment.
Written by an AI from headlines and extracts only of all events in the story · 14 Nov, 15h44
Confirmed by several sources(5)
- 7
Oral Wegovy is marketed in France from November 2.
7 independent sourcesBFMTV / RMC, Paris-Normandie, Midi Libre, 20 Minutes, La Dépêche du Midi +4
- 5
Oral Wegovy is sold at a recommended price of 169 euros per month and is not reimbursed.
5 independent sourcesMidi Libre, Le Moniteur des pharmacies, 20 Minutes, Libération, Les Échos
- 2
Waiting times in specialized consultations authorized to prescribe anti-obesity medications reach up to 18 months.
2 independent sourcesLes Échos, Le Progrès, Le Bien Public, Le Dauphiné libéré, L'Est Républicain
- 2
Oral Wegovy contains semaglutide, a GLP-1 receptor agonist.
2 independent sourcesParis-Normandie, TF1 Info / LCI
- 2
Injectable Wegovy has been available in France since 2024 and has been reimbursed under conditions since June 2026.
2 independent sourcesLe Progrès, TF1 Info / LCI
Single source so far(5)
- The European Commission authorized oral Wegovy on July 15, 2026. (according to Paris-Normandie)
- A parallel market for these medications is thriving, difficult to quantify. (according to Le Progrès, Le Bien Public, Le Dauphiné libéré, L'Est Républicain)
- Professor Emmanuel Disse said: "The more patients are treated, the more there will be bariatric surgery." (according to Le Progrès, Le Bien Public, L'Est Républicain)
- Meta Tshiteya, treated with Mounjaro for three years, lost 50 kg. (according to L'Est Républicain, Le Dauphiné libéré, Le Progrès)
AI cross-check of the headlines and extracts of 28 articles (18 outlets) · “confirmed” = reported by at least two independent outlets · 1 Nov, 22h41
Checked on the web(3)
- Not confirmed at this stage
Oral Wegovy is marketed in France from November 2.
Sources: ansm.sante.fr(official), www2.assemblee-nationale.fr(official), rtl.fr, franceinfo.fr, lagazettefrance.fr
1 Nov, 22h44
- Not confirmed at this stage
Oral Wegovy is sold at a recommended price of 169 euros per month and is not reimbursed.
Sources: ansm.sante.fr(official), rtl.fr, franceinfo.fr, lagazettefrance.fr, prescrire.org
1 Nov, 22h44
- Not confirmed at this stage
The European Commission authorized oral Wegovy on July 15, 2026.
Sources: lagazettefrance.fr, prescrire.org, ameli.fr, qare.fr, 20minutes.fr
1 Nov, 22h44
Automatic web search, official sources first · “contradicted” only when an official source is cited
Timeline
newest firstOutlets:LeftCentreRightUncategorised· badge = severity
- 15h40
LatestHors critères de la Sécu, le Wegovy coûte plus de 2 300 € par an
Le traitement anti-obésité Wegovy, non pris en charge hors critères, représente un coût annuel supérieur à 2 300 euros, faiblement couvert par les mutuelles.
JeChangeUncategorised
- 15h00
Les médicaments anti-obésité explorent de nouveaux usages thérapeutiques
Les traitements anti-obésité de type GLP-1 font l'objet de recherches sur de nouvelles indications, notamment l'AVC et les addictions, alors que leur coût reste élevé hors remboursement.
Les ÉchosCentre-right
- 09h00
Wegovy et Mounjaro remboursés : les centres spécialisés de l'obésité saturés
Depuis juin 2026, Wegovy et Mounjaro sont remboursés sous conditions en France. Les centres spécialisés de l'obésité croulent sous les demandes de patients.
BFMTV / RMCCentre
- 07h19
Wegovy : une Gersoise témoigne de sa perte de poids
Alors que l'arrivée du Wegovy en comprimés suscite des interrogations dans les pharmacies du Gers, une habitante de Fleurance raconte comment elle a perdu 30 kilos sans opération ni médicament.
La Dépêche du MidiCentre-left
In figures
Further reading
People cited
Organisations cited
Places cited
Go up the thread
Events in the story
- Hors critères de la Sécu, le Wegovy coûte plus de 2 300 € par an14 Nov
- Les médicaments anti-obésité explorent de nouveaux usages thérapeutiques14 Nov
- Wegovy et Mounjaro remboursés : les centres spécialisés de l'obésité saturés14 Nov
- Wegovy : une Gersoise témoigne de sa perte de poids14 Nov
- Près d'un Français sur cinq prêt à prendre des anti-obésité GLP-1 pour maigrir11 Nov
- Une campagne anti-grossophobie de Lilly France soupçonnée de publicité déguisée pour le Mounjaro10 Nov
- Les risques sanitaires des traitements anti-obésité Ozempic et Wegovy9 Nov
- Alerte des professionnels de santé sur des piqûres pour maigrir9 Nov
- Un ancien obèse alerte sur l'effet « dévastateur » du Wegovy sur M68 Nov
- Wegovy tablet arrives in French pharmacies8 Nov
Affected departments